Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA

Acadian Asset Management LLC lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 284.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 644,571 shares of the company’s stock after acquiring an additional 477,072 shares during the quarter. Acadian Asset Management LLC owned 0.17% of Moderna worth $17,780,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in Moderna during the 1st quarter valued at about $28,350,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Moderna during the first quarter valued at approximately $28,308,000. Jump Financial LLC boosted its stake in shares of Moderna by 5,590.0% during the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after purchasing an additional 886,567 shares in the last quarter. Invesco Ltd. increased its holdings in Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after buying an additional 877,162 shares during the period. Finally, Sessa Capital IM L.P. bought a new position in Moderna in the first quarter worth approximately $21,066,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on MRNA. Barclays dropped their target price on Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Bank of America reduced their target price on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a report on Monday. UBS Group decreased their price target on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, October 23rd. Finally, Evercore ISI set a $32.00 price objective on shares of Moderna in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.14.

Moderna Trading Up 6.7%

Shares of Moderna stock opened at $26.41 on Wednesday. The firm’s 50 day simple moving average is $25.86 and its two-hundred day simple moving average is $27.11. The firm has a market capitalization of $10.32 billion, a price-to-earnings ratio of -3.27 and a beta of 2.02. Moderna, Inc. has a 12-month low of $23.04 and a 12-month high of $48.92.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same period in the previous year, the company earned $0.03 earnings per share. The business’s quarterly revenue was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.